Aurora Biosciences to Present at Thomas Weisel Partners Healthcare Tailwinds Conference

Apr 02, 2001, 01:00 ET from Aurora Biosciences Corporation

    SAN DIEGO, April 2 /PRNewswire/ -- Aurora Biosciences Corporation
 (Nasdaq: ABSC) today announced that Aurora will present at the Thomas Weisel
 Partners Healthcare Tailwinds 2001 Conference at the Ritz-Carlton Hotel in San
 Francisco, California on Tuesday, April 3, 2001, at 12:30 p.m. PST
 (3:30 p.m. EST).  The presentation will be part of a panel session titled
 "Drug Discovery: How Technology is Changing", and will highlight how new
 technologies are enabling more efficient and productive research.
     The Aurora presentation will be webcast live and available for replay for
 30 days at: http://www.veracast.com/twp_healthcare_2001/webcasts/46208167.cfm.
     The Healthcare Tailwinds Conference 2001 features panels on proteomics and
 genomic technologies, as well as focused sessions on drug discovery, specialty
 pharmaceuticals, molecular diagnostics and other areas of healthcare.
 Panelists will include a mix of public and private company executives as well
 as Thomas Weisel Partners industry analysts.  Rounding out the conference will
 be individual presentations by some of the premier companies in the industry.
 
     Aurora Biosciences(R) develops and commercializes technologies, products
 and services to accelerate the discovery of new medicines.  Aurora's core
 technologies include a broad portfolio of proprietary fluorescence assay
 technologies and screening platforms designed to provide an integrated
 solution for drug discovery.  Our fluorescence assay technologies include our
 GeneBLAzer(TM), GenomeScreen(TM), PhosphoryLIGHT(TM) and Vivid(TM)
 technologies, as well as a broad collection of fluorescent proteins.  Our
 screening platforms include our ultra-high throughput screening system, the
 UHTSS(R) Platform, our automated master compound store, the AMCS, and our ion
 channel technology screening platform, which includes our proprietary voltage
 sensor probes and voltage ion probe reader, the VIPR(TM) subsystem.  We also
 provide assay development and screening services as part of our drug discovery
 collaborations.  Our Big Biology(TM) Initiative is an internal drug discovery
 program focused on the identification of promising preclinical candidates
 within all major classes of gene targets.  Our technologies and drug discovery
 capabilities have been commercially validated by over 20 major life sciences
 companies and research organizations, including American Home Products,
 Bristol-Myers Squibb Co., Ceres, Inc., Cystic Fibrosis Foundation, Eli Lilly &
 Co., Families of SMA, GlaxoSmithKline, Genentech, Inc., Johnson & Johnson,
 Merck & Co., Inc., NV Organon Laboratories, Pfizer, Inc., Pharmacia and Roche,
 in the form of commercialization agreements for discovery collaborations,
 research services, licenses or systems.  For additional information on
 Aurora's services and products, please contact Sales and Marketing via email
 at marcom@aurorabio.com.
 
     Statements in this press release that are not strictly historical are
 "forward-looking" statements which involve a high degree of technological and
 competitive risks and uncertainties that exist in Aurora's operations and
 business environment.  Such statements are only predictions and Aurora's
 actual events or results may differ materially from those projected in such
 forward-looking statements.  Factors that could cause or contribute to
 differences include Aurora's ability to develop and commercialize new
 technologies, as well as commercial acceptance of such technologies, Aurora's
 ability to rapidly identify promising drug candidates through its Big Biology
 initiative, Aurora's dependence on patents and proprietary rights, Aurora's
 ability to generate additional sales of products and services, Aurora's
 dependence on pharmaceutical and biotechnology collaborations and the
 development or availability of competing technologies, products or services.
 These factors and others are more fully described in Aurora's Annual Report on
 Form 10-K for the fiscal year ended December 31, 2000, as filed with the
 Securities and Exchange Commission.  For additional corporate information,
 visit the Aurora website at http://www.aurorabio.com.
     Aurora Biosciences(R), Big Biology(TM), GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM), UHTSS(R), VIPR(TM) and Vivid(TM) are trademarks of Aurora
 Biosciences Corporation.
 
     For further information please contact Doug Farrell, Senior Director,
 Investor Relations & Corporate Communications of Aurora Biosciences
 Corporation, 858-404-6767, fax, 858-404-6714, ir@aurorabio.com.
 
 

SOURCE Aurora Biosciences Corporation
    SAN DIEGO, April 2 /PRNewswire/ -- Aurora Biosciences Corporation
 (Nasdaq: ABSC) today announced that Aurora will present at the Thomas Weisel
 Partners Healthcare Tailwinds 2001 Conference at the Ritz-Carlton Hotel in San
 Francisco, California on Tuesday, April 3, 2001, at 12:30 p.m. PST
 (3:30 p.m. EST).  The presentation will be part of a panel session titled
 "Drug Discovery: How Technology is Changing", and will highlight how new
 technologies are enabling more efficient and productive research.
     The Aurora presentation will be webcast live and available for replay for
 30 days at: http://www.veracast.com/twp_healthcare_2001/webcasts/46208167.cfm.
     The Healthcare Tailwinds Conference 2001 features panels on proteomics and
 genomic technologies, as well as focused sessions on drug discovery, specialty
 pharmaceuticals, molecular diagnostics and other areas of healthcare.
 Panelists will include a mix of public and private company executives as well
 as Thomas Weisel Partners industry analysts.  Rounding out the conference will
 be individual presentations by some of the premier companies in the industry.
 
     Aurora Biosciences(R) develops and commercializes technologies, products
 and services to accelerate the discovery of new medicines.  Aurora's core
 technologies include a broad portfolio of proprietary fluorescence assay
 technologies and screening platforms designed to provide an integrated
 solution for drug discovery.  Our fluorescence assay technologies include our
 GeneBLAzer(TM), GenomeScreen(TM), PhosphoryLIGHT(TM) and Vivid(TM)
 technologies, as well as a broad collection of fluorescent proteins.  Our
 screening platforms include our ultra-high throughput screening system, the
 UHTSS(R) Platform, our automated master compound store, the AMCS, and our ion
 channel technology screening platform, which includes our proprietary voltage
 sensor probes and voltage ion probe reader, the VIPR(TM) subsystem.  We also
 provide assay development and screening services as part of our drug discovery
 collaborations.  Our Big Biology(TM) Initiative is an internal drug discovery
 program focused on the identification of promising preclinical candidates
 within all major classes of gene targets.  Our technologies and drug discovery
 capabilities have been commercially validated by over 20 major life sciences
 companies and research organizations, including American Home Products,
 Bristol-Myers Squibb Co., Ceres, Inc., Cystic Fibrosis Foundation, Eli Lilly &
 Co., Families of SMA, GlaxoSmithKline, Genentech, Inc., Johnson & Johnson,
 Merck & Co., Inc., NV Organon Laboratories, Pfizer, Inc., Pharmacia and Roche,
 in the form of commercialization agreements for discovery collaborations,
 research services, licenses or systems.  For additional information on
 Aurora's services and products, please contact Sales and Marketing via email
 at marcom@aurorabio.com.
 
     Statements in this press release that are not strictly historical are
 "forward-looking" statements which involve a high degree of technological and
 competitive risks and uncertainties that exist in Aurora's operations and
 business environment.  Such statements are only predictions and Aurora's
 actual events or results may differ materially from those projected in such
 forward-looking statements.  Factors that could cause or contribute to
 differences include Aurora's ability to develop and commercialize new
 technologies, as well as commercial acceptance of such technologies, Aurora's
 ability to rapidly identify promising drug candidates through its Big Biology
 initiative, Aurora's dependence on patents and proprietary rights, Aurora's
 ability to generate additional sales of products and services, Aurora's
 dependence on pharmaceutical and biotechnology collaborations and the
 development or availability of competing technologies, products or services.
 These factors and others are more fully described in Aurora's Annual Report on
 Form 10-K for the fiscal year ended December 31, 2000, as filed with the
 Securities and Exchange Commission.  For additional corporate information,
 visit the Aurora website at http://www.aurorabio.com.
     Aurora Biosciences(R), Big Biology(TM), GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM), UHTSS(R), VIPR(TM) and Vivid(TM) are trademarks of Aurora
 Biosciences Corporation.
 
     For further information please contact Doug Farrell, Senior Director,
 Investor Relations & Corporate Communications of Aurora Biosciences
 Corporation, 858-404-6767, fax, 858-404-6714, ir@aurorabio.com.
 
 SOURCE  Aurora Biosciences Corporation